Shopping Cart
Remove All
Your shopping cart is currently empty
Degarelix
😃Good
Catalog No. T10988Cas No. 214766-78-6
Alias FE200486 free base, FE 200486 free base
Degarelix is a peptide and selective GnRH (human gonadotropin-releasing hormone) receptor antagonist that treats prostate cancer by lowering testosterone levels in the body.
Degarelix
😃Good
Purity: 99.34%
Catalog No. T10988Alias FE200486 free base, FE 200486 free baseCas No. 214766-78-6
Degarelix is a peptide and selective GnRH (human gonadotropin-releasing hormone) receptor antagonist that treats prostate cancer by lowering testosterone levels in the body.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $60 | In Stock | In Stock | |
| 5 mg | $147 | In Stock | In Stock | |
| 10 mg | $247 | In Stock | In Stock | |
| 25 mg | $393 | In Stock | In Stock | |
| 50 mg | $553 | In Stock | In Stock | |
| 100 mg | $868 | 7-10 days | 7-10 days | |
| 200 mg | $1,170 | 7-10 days | 7-10 days |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.34%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | Degarelix is a peptide and selective GnRH (human gonadotropin-releasing hormone) receptor antagonist that treats prostate cancer by lowering testosterone levels in the body. |
| In vitro | Degarelix significantly reduced cell viability in multiple prostate-derived cell lines (1 nM–10 μM, 0–72 h), with no inhibitory effect on PC-3 cells[1].Degarelix suppressed prostate cell growth by inducing apoptosis (10 μM, 0–72 h)[1]. |
| In vivo | In rats, a single subcutaneous dose of Degarelix (1–10 mg/kg, sc) caused dose-dependent testosterone suppression lasting >30 days[1].In prostate cancer patients, Degarelix (240 mg loading dose followed by monthly 80 mg sc) rapidly reduced serum testosterone to castrate levels (≤0.5 ng/mL), without the agonist-related hormone surge, and maintained suppression for at least 1 month[1]. |
| Synonyms | FE200486 free base, FE 200486 free base |
| Molecular Weight | 1632.26 |
| Formula | C82H103ClN18O16 |
| Cas No. | 214766-78-6 |
| Smiles | C([C@@H](NC([C@@H](NC([C@@H](CC1=CC=C(NC(N)=O)C=C1)NC([C@H](CC2=CC=C(NC(=O)[C@@H]3CC(=O)NC(=O)N3)C=C2)NC([C@@H](NC([C@@H](CC=4C=CC=NC4)NC([C@@H](CC5=CC=C(Cl)C=C5)NC([C@@H](CC6=CC7=C(C=C6)C=CC=C7)NC(C)=O)=O)=O)=O)CO)=O)=O)=O)CC(C)C)=O)CCCCNC(C)C)(=O)N8[C@H](C(N[C@@H](C(N)=O)C)=O)CCC8 |
| Relative Density. | 1.325 g/cm3 (Predicted) |
| Sequence | Ac-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-Phe(4-S-dihydroorotamido)-D-Phe(4-ureido)-Leu-Lys(iPr)-Pro-D-Ala-NH2 |
| Sequence Short | XXXSXXLXPA |
Storage & Solubility Information
| Storage | keep away from moisture | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | H2O: 4 mg/mL (2.45 mM), Sonication is recommended. DMSO: 8 mg/mL (4.9 mM), Sonication is recommended. | ||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (0.61 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||
Solution Preparation Table | |||||||||||
H2O/DMSO
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Degarelix | purchase Degarelix | Degarelix cost | order Degarelix | Degarelix chemical structure | Degarelix in vivo | Degarelix in vitro | Degarelix formula | Degarelix molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.